<H1>Chapter DOI: 10.1007/978-1-60327-829-4_14<br/>Cited-By Count: 0</H1><table border="1" width="30%"><tr><td>Total References</td><td>73</td></tr><tr><td>Springer references</td><td>2</td></tr><tr><td>Non Springer references</td><td>71</td></tr><tr><td>BibStructured Count</td><td width="10%">73</td></tr><tr><td>BibUnstructured Count</td><td width="10%">0</td></tr><tr><td>DOI already available in SpringerLink</td><td>59</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>0</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>0</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>0</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>0</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1_14</td><td>BibArticle</td><td>Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513&#8211;20.</td><td><a href=http://dx.doi.org/10.1056/NEJMoa041318>10.1056/NEJMoa041318</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2_14</td><td>BibArticle</td><td>Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502&#8211;12.</td><td><a href=http://dx.doi.org/10.1056/NEJMoa040720>10.1056/NEJMoa040720</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR3_14</td><td>BibArticle</td><td>Rosenberg JE, Oh WK. What is the current status of second-line chemotherapy for castration-resistant prostate cancer? Nat Clin Pract Urol 2008;5(12):650&#8211;1.</td><td><a href=http://dx.doi.org/10.1038/ncpuro1232>10.1038/ncpuro1232</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4_14</td><td>BibArticle</td><td>Oh WK, Tay M, Huang J. Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer? Cancer 2007;109(3):477&#8211;86.</td><td><a href=http://dx.doi.org/10.1002/cncr.22439>10.1002/cncr.22439</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR5_14</td><td>BibArticle</td><td>Sternberg CN, Whelan P, Hetherington J, et al. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 2005;68:2&#8211;9.</td><td><a href=http://dx.doi.org/10.1159/000084201>10.1159/000084201</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR6_14</td><td>BibBook</td><td>Breitz HB, Roman LA, Karlov PA, et al. A phase II study of picoplatin with docetaxel and prednisone in chemotherapy-na&#239;ve patients with metastatic hormone refractory prostate cancer (CRPC). J Clin Oncol 2008; 26 (May 20 Suppl; abstr 5153).</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR7_14</td><td>BibArticle</td><td>McKeage MJ. New-generation platinum drugs in the treatment of cisplatin-resistant cancers. Expert Opin Investig Drugs 2005;14:1033&#8211;46.</td><td><a href=http://dx.doi.org/10.1517/13543784.14.8.1033>10.1517/13543784.14.8.1033</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR8_14</td><td>BibArticle</td><td>di Sant&#8217;Agnese PA. Neuroendocrine differentiation in human prostatic carcinoma. Hum Pathol 1992;23:287&#8211;96.</td><td><a href=http://dx.doi.org/10.1016/0046-8177(92)90110-O>10.1016/0046-8177(92)90110-O</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9_14</td><td>BibChapter</td><td>Huang J, diSant&#8217;Agnese PA. Neuroendocrine differentiation in prostate cancer: an overview. In: Lamberts S, editor. Advances in Oncology: The Expanding Role of Octreotide. Bristol: BioScientifica Ltd; 2002. p. 243&#8211;62.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR10_14</td><td>BibArticle</td><td>Yao JL, Madeb R, Bourne P, et al. Small cell carcinoma of the prostate: an immunohistochemical study. Am J Surg Pathol 2006;30:705&#8211;12.</td><td><a href=http://dx.doi.org/10.1097/00000478-200606000-00005>10.1097/00000478-200606000-00005</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11_14</td><td>BibArticle</td><td>Wang W, Epstein JI. Small cell carcinoma of the prostate: a morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol 2008;32:65&#8211;71.</td><td><a href=http://dx.doi.org/10.1097/PAS.0b013e318058a96b>10.1097/PAS.0b013e318058a96b</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12_14</td><td>BibArticle</td><td>Evans AJ, Humphrey PA, Belani J, van der Kwast TH, Srigley JR. Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer. Am J Surg Pathol 2006;30:684&#8211;93.</td><td><a href=http://dx.doi.org/10.1097/00000478-200606000-00003>10.1097/00000478-200606000-00003</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13_14</td><td>BibArticle</td><td>Lim KH, Huang MJ, Yang S, Hsieh RK, Lin J. Primary carcinoid tumor of prostate presenting with bone marrow metastases. Urology 2005;65:174.</td><td><a href=http://dx.doi.org/10.1016/j.urology.2004.07.010>10.1016/j.urology.2004.07.010</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR14_14</td><td>BibArticle</td><td>Reyes A, Moran CA. Low-grade neuroendocrine carcinoma (carcinoid tumor) of the prostate. Arch Pathol Lab Med 2004;128:e166&#8211;8.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR15_14</td><td>BibArticle</td><td>Ghannoum JE, DeLellis RA, Shin SJ. Primary carcinoid tumor of the prostate with concurrent adenocarcinoma: a case report. Int J Surg Pathol 2004;12:167&#8211;70.</td><td><a href=http://dx.doi.org/10.1177/106689690401200214>10.1177/106689690401200214</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR16_14</td><td>BibArticle</td><td>Abrahamsson PA, Falkmer S, Falt K, Grimelius L. The course of neuroendocrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an &#8220;endocrine marker&#8221;. Pathol Res Pract 1989;185:373&#8211;80.</td><td><a href=http://dx.doi.org/10.1016/S0344-0338(89)80016-0>10.1016/S0344-0338(89)80016-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR17_14</td><td>BibArticle</td><td>Abrahamsson PA, Wadstrom LB, Alumets J, Falkmer S, Grimelius L. Peptide-hormone- and serotonin-immunoreactive tumour cells in carcinoma of the prostate. Pathol Res Pract 1987;182:298&#8211;307.</td><td><a href=http://dx.doi.org/10.1016/S0344-0338(87)80065-1>10.1016/S0344-0338(87)80065-1</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR18_14</td><td>BibArticle</td><td>Huang J, Yao JL, di Sant&#8217;agnese PA, Yang Q, Bourne PA, Na Y. Immunohistochemical characterization of neuroendocrine cells in prostate cancer. Prostate 2006;66:1399&#8211;406.</td><td><a href=http://dx.doi.org/10.1002/pros.20434>10.1002/pros.20434</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR23_14</td><td>BibArticle</td><td>Puccetti L, Supuran CT, Fasolo PP, et al. Skewing towards neuroendocrine phenotype in high grade or high stage androgen-responsive primary prostate cancer. Eur Urol 2005;48:215&#8211;21; discussion 21&#8211;3.</td><td><a href=http://dx.doi.org/10.1016/j.eururo.2005.03.018>10.1016/j.eururo.2005.03.018</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR24_14</td><td>BibArticle</td><td>Berruti A, Dogliotti L, Mosca A, et al. Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer 2000;88:2590&#8211;7.</td><td><a href=http://dx.doi.org/10.1002/1097-0142(20000601)88:11&lt;2590::AID-CNCR23&gt;3.0.CO;2-D>10.1002/1097-0142(20000601)88:11&lt;2590::AID-CNCR23&gt;3.0.CO;2-D</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR25_14</td><td>BibArticle</td><td>Theodoropoulos VE, Tsigka A, Mihalopoulou A, et al. Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications. Urology 2005;66:897&#8211;902.</td><td><a href=http://dx.doi.org/10.1016/j.urology.2005.04.064>10.1016/j.urology.2005.04.064</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR26_14</td><td>BibArticle</td><td>Taplin ME, George DJ, Halabi S, et al. Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. Urology 2005;66:386&#8211;91.</td><td><a href=http://dx.doi.org/10.1016/j.urology.2005.03.040>10.1016/j.urology.2005.03.040</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR27_14</td><td>BibArticle</td><td>Berruti A, Mosca A, Tucci M, et al. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocr Relat Cancer 2005;12:109&#8211;17.</td><td><a href=http://dx.doi.org/10.1677/erc.1.00876>10.1677/erc.1.00876</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR28_14</td><td>BibArticle</td><td>Singh D, Febbo PG, Ross K, et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002;1:203&#8211;9.</td><td><a href=http://dx.doi.org/10.1016/S1535-6108(02)00030-2>10.1016/S1535-6108(02)00030-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR29_14</td><td>BibArticle</td><td>Cabrespine A, Guy L, Gachon F, Cure H, Chollet P, Bay JO. Circulating chromogranin A and hormone refractory prostate cancer chemotherapy. J Urol 2006;175:1347&#8211;52.</td><td><a href=http://dx.doi.org/10.1016/S0022-5347(05)00640-3>10.1016/S0022-5347(05)00640-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR30_14</td><td>BibArticle</td><td>Abdul M, Anezinis PE, Logothetis CJ, Hoosein NM. Growth inhibition of human prostatic carcinoma cell lines by serotonin antagonists. Anticancer Res 1994;14:1215&#8211;20.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR31_14</td><td>BibArticle</td><td>Dizeyi N, Bjartell A, Nilsson E, et al. Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines. Prostate 2004;59:328&#8211;36.</td><td><a href=http://dx.doi.org/10.1002/pros.10374>10.1002/pros.10374</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR32_14</td><td>BibArticle</td><td>Aprikian AG, Han K, Chevalier S, Bazinet M, Viallet J. Bombesin specifically induces intracellular calcium mobilization via gastrin-releasing peptide receptors in human prostate cancer cells. J Mol Endocrinol 1996;16:297&#8211;306.</td><td><a href=http://dx.doi.org/10.1677/jme.0.0160297>10.1677/jme.0.0160297</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR33_14</td><td>BibArticle</td><td>Reubi JC, Wenger S, Schmuckli-Maurer J, Schaer JC, Gugger M. Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6&#8211;14). Clin Cancer Res 2002;8:1139&#8211;46.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR34_14</td><td>BibArticle</td><td>Seethalakshmi L, Mitra SP, Dobner PR, Menon M, Carraway RE. Neurotensin receptor expression in prostate cancer cell line and growth effect of NT at physiological concentrations. Prostate 1997;31:183&#8211;92.</td><td><a href=http://dx.doi.org/10.1002/(SICI)1097-0045(19970515)31:3&lt;183::AID-PROS7&gt;3.0.CO;2-M>10.1002/(SICI)1097-0045(19970515)31:3&lt;183::AID-PROS7&gt;3.0.CO;2-M</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR35_14</td><td>BibArticle</td><td>Magni P, Motta M. Expression of neuropeptide Y receptors in human prostate cancer cells. Ann Oncol 2001;12(Suppl 2):S27&#8211;9.</td><td><a href=http://dx.doi.org/10.1093/annonc/12.suppl_2.S27>10.1093/annonc/12.suppl_2.S27</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR36_14</td><td>BibArticle</td><td>Wu G, Burzon DT, di Sant&#8217;Agnese PA, et al. Calcitonin receptor mRNA expression in the human prostate. Urology 1996;47:376&#8211;81.</td><td><a href=http://dx.doi.org/10.1016/S0090-4295(99)80456-7>10.1016/S0090-4295(99)80456-7</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR37_14</td><td>BibArticle</td><td>van Leenders GJ, Aalders TW, Hulsbergen-van de Kaa CA, Ruiter DJ, Schalken JA. Expression of basal cell keratins in human prostate cancer metastases and cell lines. J Pathol 2001;195:563&#8211;70.</td><td><a href=http://dx.doi.org/10.1002/path.993>10.1002/path.993</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR38_14</td><td>BibArticle</td><td>Lee LF, Louie MC, Desai SJ, et al. Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK. Oncogene 2004;23:2197&#8211;205.</td><td><a href=http://dx.doi.org/10.1038/sj.onc.1207344>10.1038/sj.onc.1207344</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR39_14</td><td>BibArticle</td><td>Huang J, Yao JL, Zhang L, et al. Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer. Am J Pathol 2005;166:1807&#8211;15.</td><td><a href=http://dx.doi.org/10.1016/S0002-9440(10)62490-X>10.1016/S0002-9440(10)62490-X</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR40_14</td><td>BibArticle</td><td>Vashchenko N, Abrahamsson PA. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol 2005;47:147&#8211;55.</td><td><a href=http://dx.doi.org/10.1016/j.eururo.2004.09.007>10.1016/j.eururo.2004.09.007</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR41_14</td><td>BibArticle</td><td>Evangelou AI, Winter SF, Huss WJ, Bok RA, Greenberg NM. Steroid hormones, polypeptide growth factors, hormone refractory prostate cancer, and the neuroendocrine phenotype. J Cell Biochem 2004;91:671&#8211;83.</td><td><a href=http://dx.doi.org/10.1002/jcb.10771>10.1002/jcb.10771</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR42_14</td><td>BibArticle</td><td>Adam RM, Kim J, Lin J, et al. Heparin-binding epidermal growth factor-like growth factor stimulates androgen-independent prostate tumor growth and antagonizes androgen receptor function. Endocrinology 2002;143:4599&#8211;608.</td><td><a href=http://dx.doi.org/10.1210/en.2002-220561>10.1210/en.2002-220561</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR43_14</td><td>BibArticle</td><td>Deeble PD, Cox ME, Frierson HF, Jr., et al. Androgen-independent growth and tumorigenesis of prostate cancer cells are enhanced by the presence of PKA-differentiated neuroendocrine cells. Cancer Res 2007;67:3663&#8211;72.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-06-2616>10.1158/0008-5472.CAN-06-2616</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR44_14</td><td>BibArticle</td><td>Huss WJ, Gregory CW, Smith GJ. Neuroendocrine cell differentiation in the CWR22 human prostate cancer xenograft: association with tumor cell proliferation prior to recurrence. Prostate 2004;60:91&#8211;7.</td><td><a href=http://dx.doi.org/10.1002/pros.20032>10.1002/pros.20032</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR45_14</td><td>BibArticle</td><td>Kaplan-Lefko PJ, Chen TM, Ittmann MM, et al. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003;55:219&#8211;37.</td><td><a href=http://dx.doi.org/10.1002/pros.10215>10.1002/pros.10215</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR46_14</td><td>BibArticle</td><td>Liao CP, Zhong C, Saribekyan G, et al. Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. Cancer Res 2007;67:7525&#8211;33.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-07-0668>10.1158/0008-5472.CAN-07-0668</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR47_14</td><td>BibArticle</td><td>Jin RJ, Wang Y, Masumori N, et al. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Cancer Res 2004;64:5489&#8211;95.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-03-3117>10.1158/0008-5472.CAN-03-3117</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR48_14</td><td>BibArticle</td><td>Uchida K, Masumori N, Takahashi A, et al. Murine androgen-independent neuroendocrine carcinoma promotes metastasis of human prostate cancer cell line LNCaP. Prostate 2006;66(5):536&#8211;45.</td><td><a href=http://dx.doi.org/10.1002/pros.20369>10.1002/pros.20369</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR49_14</td><td>BibArticle</td><td>Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85&#8211;91.</td><td><a href=http://dx.doi.org/10.1056/NEJMoa003034>10.1056/NEJMoa003034</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR50_14</td><td>BibArticle</td><td>Yagoda A, Watson RC, Natale RB, et al. A critical analysis of response criteria in patients with prostatic cancer treated with cis-diamminedichloride platinum II. Cancer 1979;44:1553&#8211;62.</td><td><a href=http://dx.doi.org/10.1002/1097-0142(197911)44:5&lt;1553::AID-CNCR2820440502&gt;3.0.CO;2-W>10.1002/1097-0142(197911)44:5&lt;1553::AID-CNCR2820440502&gt;3.0.CO;2-W</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR51_14</td><td>BibArticle</td><td>Qazi R, Khandekar J. Phase II study of cisplatin for metastatic prostatic carcinoma. An Eastern Cooperative Oncology Group study. Am J Clin Oncol 1983;6:203&#8211;5.</td><td><a href=http://dx.doi.org/10.1097/00000421-198304000-00011>10.1097/00000421-198304000-00011</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR52_14</td><td>BibArticle</td><td>Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993;71:1098&#8211;109.</td><td><a href=http://dx.doi.org/10.1002/1097-0142(19930201)71:3+&lt;1098::AID-CNCR2820711432&gt;3.0.CO;2-G>10.1002/1097-0142(19930201)71:3+&lt;1098::AID-CNCR2820711432&gt;3.0.CO;2-G</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR53_14</td><td>BibArticle</td><td>Trump DL, Marsh JC, Kvols LK, et al. A phase II trial of carboplatin (NSC 241240) in advanced prostate cancer, refractory to hormonal therapy. An Eastern Cooperative Oncology Group pilot study. Invest New Drugs 1990; 8(Suppl 1):S91&#8211;4.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR54_14</td><td>BibArticle</td><td>Canobbio L, Guarneri D, Miglietta L, et al. Carboplatin in advanced hormone refractory prostatic cancer patients. Eur J Cancer 1993;29A:2094&#8211;6.</td><td><a href=http://dx.doi.org/10.1016/0959-8049(93)90040-M>10.1016/0959-8049(93)90040-M</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR55_14</td><td>BibArticle</td><td>Miglietta L, Cannobbio L, Boccardo F. Assessment of response to carboplatin in patients with hormone-refractory prostate cancer: a critical analysis of drug activity. Anticancer Res 1995;15:2825&#8211;8.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR56_14</td><td>BibArticle</td><td>Jungi WF, Bernhard J, Hurny C, et al. Effect of carboplatin on response and palliation in hormone-refractory prostate cancer. Swiss Group for Clinical Cancer Research (SAKK). Support Care Cancer 1998;6:462&#8211;8.</td><td><a href=http://dx.doi.org/10.1007/s005200050195>10.1007/s005200050195</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR57_14</td><td>BibBook</td><td>Castagneto B, Ferraris V, Perachino M, et al. Weekly administration of standardized low-dose carboplatin (CBDCA) in the treatment of advanced hormone refractory prostate cancer (CRPC): a phase II study. Proceedings GH Cancer Symposium 2006; abstract 243.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR58_14</td><td>BibArticle</td><td>Citrin DL, Hogan TF. A phase II evaluation of adriamycin and cis-platinum in hormone resistant prostate cancer. Cancer 1982;50:201&#8211;6.</td><td><a href=http://dx.doi.org/10.1002/1097-0142(19820715)50:2&lt;201::AID-CNCR2820500205&gt;3.0.CO;2-7>10.1002/1097-0142(19820715)50:2&lt;201::AID-CNCR2820500205&gt;3.0.CO;2-7</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR59_14</td><td>BibArticle</td><td>Droz JP, Fargeot P, Laplaige P, et al. Phase II trial of the association of doxorubicin, 5 FU and cis platinum in hormonally unresponsive metastatic carcinoma of the prostate. Prog Clin Biol Res 1987;243B:235&#8211;42.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR60_14</td><td>BibArticle</td><td>Mertens WC, Porter AT, Reid RH, et al. Strontium-89 and low-dose infusion cisplatin for patients with hormone refractory prostate carcinoma metastatic to bone: a preliminary report. J Nucl Med 1992;33:1437&#8211;43.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR61_14</td><td>BibArticle</td><td>Naito S, Ueda T, Kotoh S, et al. Treatment of advanced hormone-refractory prostate carcinoma with a combination of etoposide, pirarubicin and cisplatin. Cancer Chemother Pharmacol 1995;35:225&#8211;9.</td><td><a href=http://dx.doi.org/10.1007/BF00686552>10.1007/BF00686552</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR62_14</td><td>BibArticle</td><td>Osborne CK, Blumenstein BA, Crawford ED, et al. Phase II study of platinum and mitoxantrone in metastatic prostate cancer: a Southwest Oncology Group Study. Eur J Cancer 1992;28:477&#8211;8.</td><td><a href=http://dx.doi.org/10.1016/S0959-8049(05)80080-2>10.1016/S0959-8049(05)80080-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR63_14</td><td>BibArticle</td><td>Steineck G, Reuter V, Kelly WK, et al. Cytotoxic treatment of aggressive prostate tumors with or without neuroendocrine elements. Acta Oncol 2002;41:668&#8211;74.</td><td><a href=http://dx.doi.org/10.1080/028418602321028292>10.1080/028418602321028292</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR64_14</td><td>BibArticle</td><td>Flaig TW, Barqawi A, Miller G, et al. A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone- refractory prostate cancer. Cancer 2006;107:266&#8211;74.</td><td><a href=http://dx.doi.org/10.1002/cncr.21982>10.1002/cncr.21982</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR65_14</td><td>BibArticle</td><td>Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 2001;357(9253):336&#8211;41.</td><td><a href=http://dx.doi.org/10.1016/S0140-6736(00)03639-4>10.1016/S0140-6736(00)03639-4</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR66_14</td><td>BibArticle</td><td>Berry W, Friedland D, Fleagle J, et al. A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer. Clin Genitourin Cancer 2006;5:131&#8211;7.</td><td><a href=http://dx.doi.org/10.3816/CGC.2006.n.029>10.3816/CGC.2006.n.029</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR67_14</td><td>BibArticle</td><td>Kelly WK, Curley T, Slovin S, et al. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 2001;19:44&#8211;53.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR68_14</td><td>BibArticle</td><td>Urakami S, Igawa M, Kikuno N, et al. Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer. J Urol 2002;168: 2444&#8211;50.</td><td><a href=http://dx.doi.org/10.1016/S0022-5347(05)64164-X>10.1016/S0022-5347(05)64164-X</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR69_14</td><td>BibArticle</td><td>Solit DB, Morris M, Slovin S, et al. Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma. Cancer 2003;98:1842&#8211;8.</td><td><a href=http://dx.doi.org/10.1002/cncr.11754>10.1002/cncr.11754</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR70_14</td><td>BibArticle</td><td>Kikuno N, Urakami S, Nakamura S, et al. Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer. Eur Urol 2008;51(5):1252&#8211;8.</td><td><a href=http://dx.doi.org/10.1016/j.eururo.2006.12.030>10.1016/j.eururo.2006.12.030</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR71_14</td><td>BibArticle</td><td>Oh WK, Halabi S, Kelly WK, et al. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. Cancer 2003;98:2592&#8211;8.</td><td><a href=http://dx.doi.org/10.1002/cncr.11829>10.1002/cncr.11829</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR72_14</td><td>BibArticle</td><td>Oh WK, Hagmann E, Manola J, et al. A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer. Clin Cancer Res 2005;11:284&#8211;9.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR73_14</td><td>BibArticle</td><td>Hay MP. ZD-0473 AstraZeneca. Curr Opin Investig Drugs 2000;1:263&#8211;6.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR74_14</td><td>BibArticle</td><td>McKeage MJ. Lobaplatin: a new antitumour platinum drug. Expert Opin Investig Drugs 2001;10:119&#8211;28.</td><td><a href=http://dx.doi.org/10.1517/13543784.10.1.119>10.1517/13543784.10.1.119</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR75_14</td><td>BibArticle</td><td>Ross RW, Beer TM, Jacobus S, Bubley GJ, Taplin ME, Ryan CW, Huang J, Oh WK. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer 2008;112(3):521&#8211;6.</td><td><a href=http://dx.doi.org/10.1002/cncr.23195>10.1002/cncr.23195</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR76_14</td><td>BibArticle</td><td>Nakabayashi M, Sartor O, Jacobus S, et al. Response to docetaxel (D)/carboplatin (C)-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer (CRPC). J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR78_14</td><td>BibArticle</td><td>Sternberg CN, Petrylak DP, Sartor O, et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009;27:5431&#8211;8.</td><td><a href=http://dx.doi.org/10.1200/JCO.2008.20.1228>10.1200/JCO.2008.20.1228</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>